Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Treatment Selection for Metastatic Breast Cancer
NCT00780676Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2009
- Primary completion
- May 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, selumetinib in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2009; status: terminated.
02
Drugs
dasatinibselumetinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00780676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00780676.